Literature DB >> 18854486

Animal models of Streptococcus pneumoniae disease.

Damiana Chiavolini1, Gianni Pozzi, Susanna Ricci.   

Abstract

SUMMARY: Streptococcus pneumoniae is a colonizer of human nasopharynx, but it is also an important pathogen responsible for high morbidity, high mortality, numerous disabilities, and high health costs throughout the world. Major diseases caused by S. pneumoniae are otitis media, pneumonia, sepsis, and meningitis. Despite the availability of antibiotics and vaccines, pneumococcal infections still have high mortality rates, especially in risk groups. For this reason, there is an exceptionally extensive research effort worldwide to better understand the diseases caused by the pneumococcus, with the aim of developing improved therapeutics and vaccines. Animal experimentation is an essential tool to study the pathogenesis of infectious diseases and test novel drugs and vaccines. This article reviews both historical and innovative laboratory pneumococcal animal models that have vastly added to knowledge of (i) mechanisms of infection, pathogenesis, and immunity; (ii) efficacies of antimicrobials; and (iii) screening of vaccine candidates. A comprehensive description of the techniques applied to induce disease is provided, the advantages and limitations of mouse, rat, and rabbit models used to mimic pneumonia, sepsis, and meningitis are discussed, and a section on otitis media models is also included. The choice of appropriate animal models for in vivo studies is a key element for improved understanding of pneumococcal disease.

Entities:  

Mesh:

Year:  2008        PMID: 18854486      PMCID: PMC2570153          DOI: 10.1128/CMR.00012-08

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  265 in total

1.  Experimental study of the virulence of Streptococcus pneumoniae with reduced susceptibility to penicillin.

Authors:  A B Magnúsdóttir; A Hermansson; A Melhus
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2000-09-15       Impact factor: 1.675

2.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis.

Authors:  S L Leib; D Leppert; J Clements; M G Täuber
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

4.  Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model.

Authors:  H H Tong; L E Blue; M A James; T F DeMaria
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 5.  Development of adjunctive therapies for bacterial meningitis and lessons from knockout mice.

Authors:  Robert Paul; Uwe Koedel; Hans-Walter Pfister
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

6.  Comparison of mucosal and parenteral immunisation in two animal models of pneumococcal infection: otitis media and acute pneumonia.

Authors:  Allan W Cripps; Jennelle M Kyd
Journal:  Vaccine       Date:  2006-09-25       Impact factor: 3.641

7.  Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  J P Bédos; V Rieux; J Bauchet; M Muffat-Joly; C Carbon; E Azoulay-Dupuis
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

8.  Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model.

Authors:  J Casal; L Aguilar; I Jado; J Yuste; M J Giménez; J Prieto; A Fenoll
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

9.  Experimental animal models for studying antimicrobial pharmacokinetics in otitis media.

Authors:  D M Canafax; N Nonomura; G R Erdmann; C T Le; S K Juhn; G S Giebink
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

10.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more
  45 in total

1.  A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.

Authors:  Sharavathi Guddehalli Parameswarappa; Katrin Reppe; Andreas Geissner; Petra Ménová; Subramanian Govindan; Adam D J Calow; Annette Wahlbrink; Markus W Weishaupt; Bopanna Ponnappa Monnanda; Roland Lawrence Bell; Liise-Anne Pirofski; Norbert Suttorp; Leif Erik Sander; Martin Witzenrath; Claney Lebev Pereira; Chakkumkal Anish; Peter H Seeberger
Journal:  Cell Chem Biol       Date:  2016-11-03       Impact factor: 8.116

Review 2.  Panel 5: Microbiology and immunology panel.

Authors:  Timothy F Murphy; Tasnee Chonmaitree; Stephen Barenkamp; Jennelle Kyd; Johanna Nokso-Koivisto; Janak A Patel; Terho Heikkinen; Noboru Yamanaka; Pearay Ogra; W Edward Swords; Tania Sih; Melinda M Pettigrew
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

3.  Fatal Meningitis in Swine after Intrathecal Administration of Adeno-associated Virus Expressing Syngeneic Interleukin-10.

Authors:  Mark D Unger; Josef Pleticha; James E Collins; Anibal G Armien; Jennifer L Brazzell; Laura K Newman; Lukas F Heilmann; Jodi A Scholz; Timothy P Maus; Andreas S Beutler
Journal:  Mol Ther       Date:  2017-08-01       Impact factor: 11.454

4.  Residence of Streptococcus pneumoniae and Moraxella catarrhalis within polymicrobial biofilm promotes antibiotic resistance and bacterial persistence in vivo.

Authors:  Antonia C Perez; Bing Pang; Lauren B King; Li Tan; Kyle A Murrah; Jennifer L Reimche; John T Wren; Stephen H Richardson; Uma Ghandi; W Edward Swords
Journal:  Pathog Dis       Date:  2014-02-03       Impact factor: 3.166

5.  Influenza A Virus Infection Predisposes Hosts to Secondary Infection with Different Streptococcus pneumoniae Serotypes with Similar Outcome but Serotype-Specific Manifestation.

Authors:  Niharika Sharma-Chawla; Vicky Sender; Olivia Kershaw; Achim D Gruber; Julia Volckmar; Birgitta Henriques-Normark; Sabine Stegemann-Koniszewski; Dunja Bruder
Journal:  Infect Immun       Date:  2016-11-18       Impact factor: 3.441

6.  Structural determinants of host specificity of complement Factor H recruitment by Streptococcus pneumoniae.

Authors:  David Achila; Aizhuo Liu; Rahul Banerjee; Yue Li; Erik Martinez-Hackert; Jing-Ren Zhang; Honggao Yan
Journal:  Biochem J       Date:  2015-01-15       Impact factor: 3.857

Review 7.  Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses.

Authors:  Minny Bhatty; Stephen B Pruett; Edwin Swiatlo; Bindu Nanduri
Journal:  Alcohol       Date:  2011-09       Impact factor: 2.405

8.  Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.

Authors:  Constantine Bitsaktsis; Bibiana V Iglesias; Ying Li; Jesus Colino; Clifford M Snapper; Susan K Hollingshead; Giang Pham; Diane R Gosselin; Edmund J Gosselin
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

Review 9.  Physical stress and bacterial colonization.

Authors:  Michael Otto
Journal:  FEMS Microbiol Rev       Date:  2014-09-29       Impact factor: 16.408

10.  Molecular characterization of pneumococcal isolates from pets and laboratory animals.

Authors:  Mark van der Linden; Adnan Al-Lahham; Werner Nicklas; Ralf René Reinert
Journal:  PLoS One       Date:  2009-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.